J Cho, G Ibbott, M Gillin, C Gonzalez-Lepera, U Titt and O Mawlawi

Slides:



Advertisements
Similar presentations
Harvard Medical School Massachusetts General Hospital.
Advertisements

Stefan Roesler SC-RP/CERN on behalf of the CERN-SLAC RP Collaboration
GEANT4 simulation of an ocular proton beam & benchmark against MC codes D. R. Shipley, H. Palmans, C. Baker, A. Kacperek Monte Carlo 2005 Topical Meeting.
In the past few years the usage of conformal and IMRT treatments has been increasing rapidly. These treatments employ the use of tighter margins around.
Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
University of Florida, Jacksonville, FL
TREATMENT PLANNING PHOTONS & ELECTRONS Karen P. Doppke 3/20/2007.
Tumour Therapy with Particle Beams Claus Grupen University of Siegen, Germany [physics/ ] Phy 224B Chapter 20: Applications of Nuclear Physics 24.
Interactions of charged particles with the patient I.The depth-dose distribution - How the Bragg Peak comes about - (Thomas Bortfeld) II.The lateral dose.
Tissue inhomogeneities in Monte Carlo treatment planning for proton therapy L. Beaulieu 1, M. Bazalova 2,3, C. Furstoss 4, F. Verhaegen 2,5 (1) Centre.
Design and Scheduling of Proton Therapy Treatment Centers Stuart Price, University of Maryland Bruce Golden, University of Maryland Edward Wasil, American.
Results The measured-to-predicted dose ratio criteria used by the RPC to credential institutions is , however for this work, a criteria of
بسم الله الرحمن الرحيم و قل رب زدنى علماً ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Simulating Potential Layouts for a Proton Therapy Treatment Center Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil-
Heavy Ion Tumor Therapy
Научно-практический центр протонной лучевой терапии и радиохирургии (Москва-Дубна) A SYSTEM FOR MEASUREMENT OF A THERAPEUTIC PROTON BEAM DOSE DISTRIBUTION.
Patient Plan Results: Table 3 shows the ratio of the Pinnacle TPS calculation to the DPM recalculation for the mean dose from selected regions of interest.
Evaluation of the Performance of the Fast Scanning Platform of an OCT System Malcolm Heard 1, Miguel Herrera 1, Geoffrey Ibbott 1 1 Department of Radiation.
Applications of Geant4 in Proton Radiotherapy at the University of Texas M.D. Anderson Cancer Center Jerimy C. Polf Assistant Professor Department of Radiation.
Comparison of Clinical Parameters for Proton Therapy in the United States Paige Summers, MS.
Bragg Peak By: Megan Whitley. Bragg Peak  Bragg Peak is the characteristic exhibited by protons that makes them SO appealing for cancer treatment. 
Ye, Sung-Joon, Ph.D. Ove, Roger, M.D., Ph.D.; Shen, Sui, Ph.D.
DEPT OF RADIATION ONCOLOGY Clinical Evaluation of a Novel 4D-CBCT Reconstruction Scheme Based on Simultaneous Motion Estimation and Image Reconstruction.
Investigation of 3D Dosimetry for an Anthropomorphic Spine Phantom R. Grant 1,2, G. Ibbott 1, J. Yang 1, J. Adamovics 3, D Followill 1 (1)M.D. Anderson.
S Scarboro 1,2, D Cody 1,2, D Followill 1,2, P Alvarez 1, M McNitt-Gray 3, D Zhang 3, L Court 1,2, S Kry 1,2 * 1 UT MD Anderson Cancer Center, Houston,
Introduction The Radiological Physics Center (RPC) anthropomorphic quality assurance (QA) phantom program is one tool the RPC uses to remotely audit institutions.
Purpose N-isopropylacrylamide (NIPAM) polymer gel dosimeters were employed to verify the dose distribution of clinical intensity modulated radiation therapy.
Thickness of CZT detector 110 MeV140 MeV DETECTOR A (1 mm CZT + 5 mm CZT) DETECTOR B (1 mm CZT + 10 mm CZT) DETECTOR C (1 mm CZT + 15 mm CZT) A. Generation.
Development of elements of 3D planning program for radiotherapy Graphical editor options  automated enclose of contour  correction of intersections 
1 NANO AMPLIFIED THERAPY INFN-Milano, INFN-Torino, INFN-Pisa, INFN- Roma3, CNR-Pisa, University of Torino - Biotechnology Department.
A comparison between soft tissue and bone registration techniques for prostate radiotherapy Richard Small, Paul Bartley, Audrey Ogilvie, Nick West and.
5.5 Medical Applications Using Radioactivity
Characterization of proton-activated implantable markers for proton range verification using PET J. Cho1, G. Ibbott1, M. Kerr1, R. A. Amos2, F. Stingo1,
J Cho, G Ibbott, M Kerr, R Amos, and O Mawlawi
Methods & Materials (continued)
RHD-DoPET CNAO test beam result (may 2014)
CT Scan vs MRI.
Proton beam range verification using proton activated fiducials and off-site PET AAPM Best in Physics, Indianapolis, August 7, 2013 Cho J1, Ibbott G1,
INTERCOMPARISON P3. Dose distribution of a proton beam
You Zhang, Jeffrey Meyer, Joubin Nasehi Tehrani, Jing Wang
Kasey Etreni BSc., MRT(T), RTT, CTIC
Electron Beam Therapy.
Radiological Sciences Department Ph.D., Paris-Sud 11 University
Proton range verification with PET: 68Zn, Cu and polycarbonate activation SNMMI Young Investigator Symposium, Vancouver, June 9, 2013 Cho J1, Ibbott.
Left Posterior Superior Right Anterior Inferior
Development and characterization of the Detectorized Phantom for research in the field of spatial fractionated radiation therapy. D. Ramazanov, V. Pugatch,
Template Matching Can Accurately Track Tumor Evaluation of Dose Calculation of RayStation Planning System in Heterogeneous Media Huijun Xu, Byongyong Yi,
A Brachytherapy Treatment Planning Software Based on Monte Carlo Simulations and Artificial Neural Network Algorithm Amir Moghadam.
Comparison of carina- versus bony anatomy-based registration for setup verification in esophageal cancer image-guided radiotherapy Melanie Machiels* 1,
Chain Reactions Chain Reaction - the series of repeated fission reactions caused by the release of neutrons in each reaction.
AAPM Annual Meeting, Anaheim, California July 13, 2015
Karla Leach, BS, CMD Texas Center for Proton Therapy-Irving, TX
Implementation of Object Spot Avoidance in Proton Pencil Beam Treatment on Whole Breast with Implant Metal Injector Peng Wang, PhD, DABR, Karla Leach,
Reducing Treatment Time and MUs by using Dynamic Conformal Arc Therapy for SBRT Breath-Hold Patients Timothy Miller, Sebastian Nunez Albermann, Besil Raju,
Recent Advances in Bronchoscopic Treatment of Peripheral Lung Cancers
PET-utilized proton range verification using 13N signals
Feasibility of using O-18 for PET proton range verification
Novel optical imaging technique to determine the 3-D orientation of collagen fibers in cartilage: variable-incidence angle polarization-sensitive optical.
Radioisotopes in Medicine
Applications of Dual-Energy Computed Tomography for the Evaluation of Head and Neck Squamous Cell Carcinoma  Reza Forghani, MD, PhD, Hillary R. Kelly,
L. A. den Otter. , R. M. Anakotta. , M. Dieters. , C. T. Muijs. , S
Emma Hedin, Anna Bäck, Roumiana Chakarova 
Precision and accuracy of computed tomography foot measurements
Kiran Devisetty, MD, Joseph K. Salama, MD  Journal of Thoracic Oncology 
Innovations in the Radiotherapy of Non–Small Cell Lung Cancer
Hot and cold spots are common problems associated with planning:
Figure 3 Craniospinal irradiation proton therapy for medulloblastoma
Improving Image Accuracy of ROI in CT Using Prior Image
Atoms and Nuclear Radiation Atoms and Isotopes
Planning techniques of proton boost
Presentation transcript:

Proton Beam Range Verification using Proton Activated Fiducials and Off-site PET J Cho, G Ibbott, M Gillin, C Gonzalez-Lepera, U Titt and O Mawlawi The University of Texas MD Anderson Cancer Center, Houston, TX AAPM Best in Physics, Indianapolis, 2013 Talk session: Novel Imaging Tech & Appl 4:40PM August 7th (Wed) at 500 Ballroom Motivations The conventional proton range verification using PET takes advantage of endogenous tissue activation in combination with Monte Carlo simulation. However, this approach has the following limitations: Weak tissue activation at the end of the proton beam Perfusion driven activity washout Short decay half-life (need of costly in-room PET) Monte Carlo uncertainties in Elemental tissue composition conversion Nuclear cross sections Biological washout model The purpose of this work was to develop a novel proton range verification method that is not subject to the above limitations. By taking advantage of patient-implantable fiducial markers that are strongly activated by low energy protons and decay with relatively long half-lives, a proton range verification can be realized using commonly available off-site PET scanners. In-Air Irradiation Embedded Irradiation: Lung tissue 30 min PET scan after 126 min delay (a) (a) (a) (b) (b) Fig. 4: 68Zn (98% enriched) and Cu foils and polycarbonate sheets (as a tissue substitute) are placed at 4 distal fall-off depths and irradiated by a proton beam. Cu has 69% 63Cu. Fig. 11: A coronal plane view with a row of 25mm3 Cu foils. (a) PET/CT fusion images. (b) Treatment plan generated isodose curves with respect to CT image. With the borderline of 95% isodose curve, Cu foils located at higher dose are activated. Fig. 9: (a) Foil locations relative to PDD. (b) Foil at depth 4 is marginally activated and foil at depth 5 is not activated. Therefore, the proton range can be estimated with ±5mm uncertainty. Fig. 2: 68Zn and 63Cu have large cross sections at low proton energies and decay with relatively long half-lives. As a result, they are activated strongly at the proton distal fall-off region where proton energy is low. Endogenous tissue elements (12C and 16O) are shown for comparison. (b) Fig. 7: (a) Balsa wood (as lung substitute) with embedded 68Zn and Cu foils at 4 distal fall-off depths and irradiated by a proton beam. (b) CT scan and treatment plan of the balsa wood show isodose curves relative to each depth. Embedded irradiation: Soft tissue Parodi et al, NIH public access 2007 30 min PET scan after 48 min delay Background Fig. 5: Depths of PC (polycarbonate), 68Zn and Cu relative to PDD and their PET/CT fusion images. Only 68Zn and 63Cu show PET signals at deeper depths (not PC). 68Zn and 63Cu signals are strong despite its volume is 7.6 times smaller than PC. Fig. 12: A coronal plane view with a row of 25mm3 68Zn foils. With the borderline of 50% isodose curve, 68Zn foils located at higher dose are activated. Foil 1 is not activated because protons activating this foil is too high (see fig. 2). (a) (a) (b) Conclusions Higher activation of 68Zn and Cu at the proton dose distal fall-off region and their long half-lives indicate the possibility of using those materials as patient implantable fiducial markers for proton range verification using off-site PET scanners. Signal reduced Fig. 3: Hypothetical images of proton activated fiducial markers made of 68Zn or 63Cu implanted in a patient prior to proton therapy. (a) One marker is implanted near the proton distal fall-off and one just outside the proton range. (b) The marker implanted near the distal fall-off is activated (red) and the other marker outside the proton range is not activated (green). In this regard, the proton range can be approximated to be fall somewhere between the two fiducials. (b) Fig. 1: Proton range uncertainty can result in overdosage in critical organs or underdosage in tumor. It is crucial to verify the proton range accurately. Fig. 10: (a) Soft-tissue phantom made of beef cut diagonally is embedded with 68Zn and Cu foils and is irradiated by a proton beam. Each of 5 different coronal planes contains a different row of foils. (b) Locations of embedded foils relative to PDD. Fig. 8: PET/CT fusion images of each depth in the beam’s eye view. Signals from foils are much stronger than balsa wood. Signals are reduced with depth. Foil is marginally activated at depth 4. Fig. 6: Comparison of measured PDD and activity (PET signal) with Monte Carlo simulation. Activity fall-offs follow the dose fall-off with 1~2 mm offsets.